CSPC Pharma (01093) has announced that its first-in-class PD-1/IL-15 bispecific fusion protein, SYS6090 (JMT108), has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

The designation covers the treatment of patients with microsatellite stable (MSS) or mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) who have shown disease progression following prior standard systemic therapy.

Colorectal cancer remains a major public health challenge in the United States, ranking as the third most common cancer and the second leading cause of cancer-related deaths. According to SEER data from the National Cancer Institute, the five-year survival rate for patients with distant metastatic CRC stands at approximately 17%.

Among MSS/pMMR mCRC patients who have received three or more lines of prior therapy, median overall survival typically remains under 12 months, highlighting a substantial unmet clinical need.

MSS/pMMR mCRC is considered a typical cold tumor with limited response to standard immunotherapies. SYS6090 is a bispecific fusion protein designed to simultaneously block PD-1 and activate the IL-15 signaling pathway.

Its uniquely engineered asymmetric structure directs IL-15 activity in a PD-1-dependent manner, potentially enabling selective remodeling of the resistant or immunologically cold tumor microenvironment and reactivation of exhausted effector cells while minimizing immune-related toxicity.

Supporting data for the Fast Track designation includes preclinical study results as well as data from an ongoing Phase I clinical trial being conducted concurrently in China and the United States.

The FDA's Fast Track designation recognizes the product's potential to address serious or life-threatening conditions and is expected to expedite its development and regulatory review process in the U.S. and globally.